PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…
News
CHOLANGITIS
NewsLivdelzi maintains benefits for up to 3 years in PBC: Phase 3 data
Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…
FATTY LIVER DISEASE
NewsNew drug HU6 cuts liver fat but preserves muscle mass
HU6, an experimental oral therapy from Rivus Pharmaceuticals, safely and effectively reduced liver fat and led to fat-selective weight loss in adults with metabolic…
BILIARY ATRESIA
NewsBetter to have Kasai surgery before liver transplant for biliary atresia
For infants with biliary atresia, undergoing standard Kasai surgery — a procedure to restore the flow of the digestive fluid bile in the body…
Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…
CHOLESTASIS
NewsNovel gene mutation is likely cause of newborn’s rare liver disease
A novel mutation in the NR1H4Â gene was the likely cause of progressive familial intrahepatic cholestasis (PFIC) type 5 in a baby girl in Tunisia,…
FATTY LIVER DISEASE
NewsEmerging forever chemical may drive fatty liver disease
Exposure to a human-made chemical called perfluoroheptanoic acid (PFHpA) may increase the risk and severity of fatty liver disease in adolescents with obesity, according…
ALAGILLE SYNDROME
NewsWhy Mexican children with Alagille lag behind in getting proper care
Children in Mexico living with the complex genetic disease Alagille syndrome have limited access to essential care, including confirmatory genetic testing at diagnosis and,…
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…
Recent Posts
- For girl in Asia, limited access to genetic testing delayed an Alagille diagnosis
- FDA gives bepirovirsen priority review for chronic hepatitis B
- Starting disease marker levels may shape Iqirvo response in PBC
- The possibility for liver function to improve brings me hope
- New mouse model could help guide PFIC3 treatment research